ATE224736T1 - Kombinationsprodukt, enthaltend eine nukleinsäure und eine substanz, die die extrazellulärematrix desorganisiert, zur verwendung in gentherapie - Google Patents
Kombinationsprodukt, enthaltend eine nukleinsäure und eine substanz, die die extrazellulärematrix desorganisiert, zur verwendung in gentherapieInfo
- Publication number
- ATE224736T1 ATE224736T1 AT98928391T AT98928391T ATE224736T1 AT E224736 T1 ATE224736 T1 AT E224736T1 AT 98928391 T AT98928391 T AT 98928391T AT 98928391 T AT98928391 T AT 98928391T AT E224736 T1 ATE224736 T1 AT E224736T1
- Authority
- AT
- Austria
- Prior art keywords
- disorganizes
- nucleic acid
- extracellular matrix
- gene therapy
- substance
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Public Health (AREA)
- Plant Pathology (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Saccharide Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9706600A FR2763958A1 (fr) | 1997-05-29 | 1997-05-29 | Produit de combinaison associant un acide nucleique a une substance desorganisant la matrice extracellulaire pour la therapie genique |
PCT/FR1998/001084 WO1998053853A1 (fr) | 1997-05-29 | 1998-05-29 | Produit de combinaison associant un acide nucleique a une substance desorganisant la matrice extracellulaire pour la therapie genique |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE224736T1 true ATE224736T1 (de) | 2002-10-15 |
Family
ID=9507375
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT98928391T ATE224736T1 (de) | 1997-05-29 | 1998-05-29 | Kombinationsprodukt, enthaltend eine nukleinsäure und eine substanz, die die extrazellulärematrix desorganisiert, zur verwendung in gentherapie |
Country Status (12)
Country | Link |
---|---|
US (1) | US6258791B1 (de) |
EP (1) | EP0980263B1 (de) |
JP (1) | JP2002500662A (de) |
AT (1) | ATE224736T1 (de) |
AU (1) | AU752146B2 (de) |
CA (1) | CA2291590A1 (de) |
DE (1) | DE69808274T2 (de) |
DK (1) | DK0980263T3 (de) |
ES (1) | ES2181234T3 (de) |
FR (1) | FR2763958A1 (de) |
PT (1) | PT980263E (de) |
WO (1) | WO1998053853A1 (de) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0998945A1 (de) * | 1998-09-30 | 2000-05-10 | Transgene S.A. | Verwendung von Magnesium (Mg2+) zur Erhöhung der Gen-Verabreichung bei Gentherapie |
US7691370B2 (en) | 1998-10-15 | 2010-04-06 | Canji, Inc. | Selectivity replicating viral vector |
AU2038900A (en) * | 1998-12-04 | 2000-06-26 | Genzyme Corporation | Methods for increasing the efficiency of gene transfer |
ES2203230T3 (es) * | 1998-12-23 | 2004-04-01 | Esparma Gmbh | Hialuronatoliasa como promotor de penetracion en agentes topicos. |
IL152420A0 (en) * | 2001-02-23 | 2003-05-29 | Novartis Ag | Novel oncolytic adenoviral vectors |
JP2005524389A (ja) * | 2001-11-26 | 2005-08-18 | イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー | 宿主組織内への核酸分子の電気的遺伝子導入の増強 |
US7144870B2 (en) | 2002-02-15 | 2006-12-05 | Research Development Foundation | Hyaluronic acid mediated adenoviral transduction |
DE10211457A1 (de) * | 2002-03-12 | 2003-09-25 | Knoell Hans Forschung Ev | Verwendung von Hyaluronatlyase zur Behandlung von Myokardinfarkten |
EP1521523A4 (de) * | 2002-05-20 | 2006-04-19 | Univ Texas | Verfahren und zusammensetzungen zur zuführung von enzymen und nukleinsäuremolekülen an gehirn, knochen und andere gewebe |
WO2004098534A2 (en) * | 2003-02-24 | 2004-11-18 | Therion Biologics Corporation | Methods for delivering angiogenic modulators using pox viruses |
ATE448323T1 (de) * | 2003-03-05 | 2009-11-15 | Halozyme Inc | Lösliches hyaluronidase-glycoprotein (shasegp), verfahren zu seiner herstellung, verwendungen und dieses enthaltende pharmazeutische zusammensetzungen |
US20050014714A1 (en) * | 2003-06-04 | 2005-01-20 | The Johns Hopkins University | Gene delivery to organs |
EP1648931B1 (de) | 2003-07-21 | 2011-02-09 | Transgene S.A. | Multifunktionelle cytokine |
US7888201B2 (en) * | 2003-11-04 | 2011-02-15 | Taiwan Semiconductor Manufacturing Company, Ltd. | Semiconductor-on-insulator SRAM configured using partially-depleted and fully-depleted transistors |
US7572613B2 (en) * | 2004-06-25 | 2009-08-11 | Klein Jeffrey A | Drug delivery system for accelerated subcutaneous absorption |
JP2007175021A (ja) * | 2005-12-28 | 2007-07-12 | Sysmex Corp | 大腸がんのリンパ節転移マーカー |
WO2008101098A2 (en) * | 2007-02-15 | 2008-08-21 | Allergan, Inc. | Use of botulinum toxin and enzymes for treating bladder or prostata disorders, or hyperhydrosis |
US8357531B2 (en) | 2007-07-03 | 2013-01-22 | Transgene S.A. | Immortalized avian cell lines |
US20100305500A1 (en) * | 2009-05-29 | 2010-12-02 | Pacira Pharmaceuticals, Inc. | Hyaluronidase as an adjuvant for increasing the injection volume and dispersion of large diameter synthetic membrane vesicles containing a therapeutic agent |
WO2012058483A1 (en) | 2010-10-28 | 2012-05-03 | Pacira Pharmaceuticals, Inc. | A sustained release formulation of a non-steroidal anti-inflammatory drug |
WO2014066443A1 (en) | 2012-10-23 | 2014-05-01 | Emory University | Gm-csf and il-4 conjugates, compositions, and methods related thereto |
WO2018093932A2 (en) | 2016-11-16 | 2018-05-24 | Immunomic Therapeutics, Inc. | Nucleic acids for treatment of allergies |
WO2018094253A1 (en) | 2016-11-18 | 2018-05-24 | Pacira Pharmaceuticals, Inc. | Zinc meloxicam complex microparticle multivesicular liposome formulations and processes for making the same |
JP2020517271A (ja) | 2017-04-22 | 2020-06-18 | イミュノミック セラピューティックス, インコーポレイテッドImmunomic Therapeutics, Inc. | 改良lamp構築物 |
EP3618854A1 (de) | 2017-05-02 | 2020-03-11 | Immunomic Therapeutics, Inc. | Lamp (lysosomale assoziierte membranprotein)-konstrukte mit krebsantigenen |
JP2021523185A (ja) | 2018-05-15 | 2021-09-02 | イミュノミック セラピューティックス, インコーポレイテッドImmunomic Therapeutics, Inc. | アレルゲンを含む改善されたlamp構築物 |
US20240108703A1 (en) | 2019-10-18 | 2024-04-04 | Immunomic Therapeutics, Inc. | Improved LAMP Constructs Comprising Cancer Antigens |
US20220401583A1 (en) * | 2021-06-16 | 2022-12-22 | BioViva USA, Inc. | Treatment of age-related cognitive decline using genetically modified viral vectors |
WO2023201201A1 (en) | 2022-04-10 | 2023-10-19 | Immunomic Therapeutics, Inc. | Bicistronic lamp constructs comprising immune response enhancing genes and methods of use thereof |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU7312891A (en) * | 1990-02-12 | 1991-09-03 | Board Of Regents, The University Of Texas System | Satellite cell proliferation in adult skeletal muscle |
US5616483A (en) * | 1992-06-11 | 1997-04-01 | Aktiebolaget Astra | Genomic DNA sequences encoding human BSSL/CEL |
US5739118A (en) * | 1994-04-01 | 1998-04-14 | Apollon, Inc. | Compositions and methods for delivery of genetic material |
FR2732895B1 (fr) | 1995-04-11 | 1997-05-16 | Pasteur Merieux Serums Vacc | Utilisation d'un compose amphipathique cationique comme agent de transfection, comme adjuvant de vaccin, ou comme medicament |
US5858351A (en) | 1996-01-18 | 1999-01-12 | Avigen, Inc. | Methods for delivering DNA to muscle cells using recombinant adeno-associated virus vectors |
US6177410B1 (en) | 1997-12-05 | 2001-01-23 | Vanderbilt University | Therapeutic methods for prostate cancer |
-
1997
- 1997-05-29 FR FR9706600A patent/FR2763958A1/fr active Pending
-
1998
- 1998-05-29 US US09/424,741 patent/US6258791B1/en not_active Expired - Fee Related
- 1998-05-29 CA CA002291590A patent/CA2291590A1/fr not_active Abandoned
- 1998-05-29 DK DK98928391T patent/DK0980263T3/da active
- 1998-05-29 ES ES98928391T patent/ES2181234T3/es not_active Expired - Lifetime
- 1998-05-29 PT PT98928391T patent/PT980263E/pt unknown
- 1998-05-29 JP JP50034299A patent/JP2002500662A/ja not_active Ceased
- 1998-05-29 DE DE69808274T patent/DE69808274T2/de not_active Expired - Lifetime
- 1998-05-29 AU AU80238/98A patent/AU752146B2/en not_active Ceased
- 1998-05-29 AT AT98928391T patent/ATE224736T1/de not_active IP Right Cessation
- 1998-05-29 EP EP98928391A patent/EP0980263B1/de not_active Expired - Lifetime
- 1998-05-29 WO PCT/FR1998/001084 patent/WO1998053853A1/fr active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
CA2291590A1 (fr) | 1998-12-03 |
EP0980263A1 (de) | 2000-02-23 |
DE69808274D1 (de) | 2002-10-31 |
WO1998053853A1 (fr) | 1998-12-03 |
AU752146B2 (en) | 2002-09-05 |
EP0980263B1 (de) | 2002-09-25 |
JP2002500662A (ja) | 2002-01-08 |
ES2181234T3 (es) | 2003-02-16 |
AU8023898A (en) | 1998-12-30 |
US6258791B1 (en) | 2001-07-10 |
DE69808274T2 (de) | 2003-05-15 |
FR2763958A1 (fr) | 1998-12-04 |
DK0980263T3 (da) | 2003-02-03 |
PT980263E (pt) | 2003-02-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE224736T1 (de) | Kombinationsprodukt, enthaltend eine nukleinsäure und eine substanz, die die extrazellulärematrix desorganisiert, zur verwendung in gentherapie | |
DE69535540D1 (de) | Zusammensetzung enthaltend nukleinsäuren und kationische polymere, zubereitung und verwendung | |
BR9915597A (pt) | Amplificação multiplex de loci repetidos em tandem curtos | |
ATE373672T1 (de) | Synthese von methoxynukleoside und enzymatische nukleisäure moleküle | |
ZA200405390B (en) | Entrapped binding proteins as biosensors | |
DE69942459D1 (de) | Isolierte nukleinsäuremoleküle die t-zellen induzierbare faktoren kodieren (tif), kodierte proteine und ihre anwendung | |
UA74325C2 (uk) | ГЕТЕРОЦИКЛІЧНІ ІНГІБІТОРИ р38, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЇХ МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ ЗА ЇХ ДОПОМОГОЮ | |
BR0210593A (pt) | polinucleotìdeos de defensina e métodos de uso | |
AU2001268468A1 (en) | Use of nucleotide analogs in the analysis of oligonucleotide mixtures and in highly multiplexed nucleic acid sequencing | |
HK1033582A1 (en) | Antibodies to death receptor 4 (dr4) and uses thereof | |
HUP0001937A2 (hu) | Új vegyületek, eljárás előállításukra és alkalmazásuk nukleinsavak sejtekbe való bevitelére | |
DE69732535D1 (de) | Oligonucleotidzusammenstellung und verfahren zur regulierung der protein b7 expression | |
DE60235005D1 (de) | Nachweis der instabilität von mikrosatelliten und | |
EP1123414A4 (de) | Antisense modulation der expression von integrin alpha 4 | |
WO2001096373A3 (en) | Fluorescent timer proteins and methods for their use | |
ATE277171T1 (de) | Ikk-alpha proteine, nukleinsäuren und verfahren | |
WO2000030667A3 (en) | Compositions and methods using lactadherin or variants thereof | |
ATE305037T1 (de) | Peptide, die fähig sind die sh3-domäne des gap- proteins zu binden, ihre kodierende dns, ihre zubereitung und verwendung | |
CA2273855A1 (en) | Novel feline fc epsilon receptor alpha chain nucleic acid molecules, proteins and uses thereof | |
ATE474047T1 (de) | Nukleinsäuremolekül, die für die alpha-kettedes pferde-fc-epsilon-rezeptors kodieren, korrespondierende proteine und ihre verwendungen | |
DE69728415D1 (de) | Produkte des keratinocyten-wachstumsfaktors 2 (kgf-2) | |
HUP0101393A1 (hu) | Redukáló körülményekre érzékeny transzfektáló kompozíciók, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
DE59711887D1 (de) | Dna zur abschätzung des progressionspotentials von zervixläsionen | |
HUP0102455A2 (hu) | Új nukleinsav-transzfer ágensek, ezeket tartalmazó készítmények és alkalmazásuk | |
ID27964A (id) | Turuna-azabisikloheptana n-tersubstitusi, pembuatan dan penggunaannya |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 0980263 Country of ref document: EP |
|
REN | Ceased due to non-payment of the annual fee |